Disease · MONDO_0012727
Kawasaki disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Kawasaki disease. Diseases, record MONDO_0012727. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012727
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Kawasaki syndrome, acute febrile mucocutaneous lymph node syndrome, acute febrile mucocutaneous lymph node syndrome [MCLS], infantile polyarteritis nodosa, mucocutaneous lymph node syndrome
- Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Approval | EMA Human Drugs | 9 | 5 | 0 | Drugs and targets | |
| INFLIXIMAB | CHEMBL1201581 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| POLYETHYLENE GLYCOL | CHEMBL1201478 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANAKINUMAB | CHEMBL1201834 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEFIBROTIDE | CHEMBL2108396 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 2 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| ADORA1 | Adenosine receptor A1 | 1 | Adenosine A1 receptor agonist | Phase 2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| F2 | Prothrombin | 1 | Thrombin antagonist | Phase 2 | https://conductscience.org/library/genes/2147 | Drugs and targets |
| IL1B | Interleukin-1 beta | 1 | Interleukin-1 beta inhibitor | Phase 2 | https://conductscience.org/library/genes/3553 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| PLG | Plasminogen | 1 | Plasminogen activator | Phase 2 | https://conductscience.org/library/genes/5340 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00841789 | A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease | Phase 2 | 205 | 2023-05-06 | Mucocutaneous Lymph Node Syndrome, Kawasaki Disease | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT00760435 | Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease | Phase 3 | 196 | 2014-11-13 | Kawasaki Disease | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03065244 | KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) | Phase 3 | 105 | 2021-12-03 | Mucocutaneous Lymph Node Syndrome | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04898231 | MIS-C Comparative Effectiveness Study | Phase 2/3 | 73 | 2025-11-04 | Multisystem Inflammatory Syndrome-Children | ANAKINRA, INFLIXIMAB, METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT01596335 | Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease | Phase 3 | 31 | 2018-09-26 | Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin | INFLIXIMAB, POLYETHYLENE GLYCOL | Its record names the disease | ClinicalTrials.gov |
| NCT00271570 | Infliximab (Remicade) for Patients With Acute Kawasaki Disease | Phase 1 | 24 | 2009-12-29 | Kawasaki Disease | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02179853 | Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease | Phase 1/2 | 22 | 2024-03-04 | Kawasaki Disease | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
| NCT04747847 | Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease | Early phase 1 | 5 | 2026-02-25 | Kawasaki Disease | ANAKINRA, ATORVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT04078568 | Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease | Phase 3 | 3,208 | Kawasaki Disease | ASPIRIN, PREDNISOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02359643 | Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease | Not applicable | 300 | Kawasaki Disease | ASPIRIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1 -Etanercept vs ARM 2 Placebo: Determine if Etanercept Treatment Alters the Rate of Coronary Artery Dilation and Disease (CAD) at 2 and 6 Weeks After Treatment in Patients With Dilated Coro | 56 of 100 | 53 of 101 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs ARM 2 Placebo: IVIG Refractory | 13 of 100 | 22 of 101 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs Arm -2 Placebo: deaths from any cause | 0 of 99 | 0 of 102 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs Arm -2 Placebo: serious adverse events | 9 of 99 | 10 of 102 | 201 | NCT00841789 | Trial comparisons |
| Infliximab Arm vs Placebo Arm: serious adverse events | 22 of 98 | 17 of 98 | 196 | NCT00760435 | Trial comparisons |
| Infliximab vs Placebo: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion | 11 of 98 | 11 of 97 | 195 | NCT00760435 | Trial comparisons |
| IVIG vs Infliximab: Number of Participants With IVIG and Infliximab Infusion Reactions and Complications | 1 of 49 | 2 of 54 | 103 | NCT03065244 | Trial comparisons |
| IVIG vs Infliximab: deaths from any cause | 0 of 49 | 0 of 54 | 103 | NCT03065244 | Trial comparisons |
| IVIG vs Infliximab: serious adverse events | 27 of 49 | 10 of 54 | 103 | NCT03065244 | Trial comparisons |
| IVIG vs Infliximab: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. | 25 of 49 | 40 of 52 | 101 | NCT03065244 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials17
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012727
GET https://conductscience.org/api/diseases/v1/MONDO_0012727/drugs